Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients by Salgado, R et al.
An interim conclusion of the ongoing translational research
concerning tumour angiogenesis is that obtaining quantitative
information of this process in cancer patients seems to add prog-
nostic and predictive power to the currently used tumour staging
systems (Gasparini, 1996). Angiogenesis is an element of the
stromal reaction to tumour cell populations and supports their
growth (Folkman, 1990), invasion (Skobe et al, 1997) and meta-
stasis (Liotta and Saidel, 1974). Although counting individual
microvessels on immunostained tissue sections is feasible and
informative (Vermeulen et al, 1996), a more observer-independent
and dynamic method of quantifying angiogenesis in cancer
patients is based on the assessment of circulating angiogenic factor
concentrations.
Serum levels of basic fibroblast growth factor (bFGF) predicted
accelerated growth of lung metastases in patients with renal cell
carcinoma (Duensig et al, 1995). In advanced colorectal cancer,
elevated serum bFGF and serum vascular endothelial growth factor
(VEGF) levels were closely associated with short estimated volume
doubling times of the metastases (Dirix et al, 1996). Serum angio-
genic factor levels might also be used to select patients for a
specific treatment. In metastatic renal cell carcinoma patients,
elevated serum levels of bFGF predicted response to interferon
alpha (IFN-a) treatment (Vermeulen et al, 1997). In colorectal
cancer, preoperative serum VEGF measurements correlated with T
stage and the extent of nodal involvement (Kumar et al, 1998).
Evaluation of response to treatment might be another application of
assessing circulating angiogenic factors in cancer patients. Patients
with response to treatment had less frequently elevated bFGF and/
or VEGF serum levels than patients with progressive tumours of
various histological types (Dirix et al, 1997). Survival of cancer
patients has been estimated using pretreatment serum angiogenic
factor measurements. High VEGF concentrations were associated
with shorter survival in non-Hodgkin’s lymphoma (Salven et al,
1997) and in small-cell lung cancer (Salven et al, 1998). Elevated
serum bFGF predicted a worse outcome in renal cell carcinoma
patients (Dosquet et al, 1997).
Recently, preliminary evidence for VEGF storage by platelets in
cancer patients has been described (Verheul et al, 1997; Banks
et al, 1998). Serum VEGF concentrations correlated with platelet
numbers in breast cancer patients during chemotherapy. After
induction of platelet aggregation, the VEGF content in the super-
natant of the platelet suspension was significantly increased
(Verheul et al, 1997). Comparable results have been reported by
Banks et al (1998). Activated platelets release VEGF together with
b-thromboglobulin, suggesting that VEGF resides in the a-
granules of platelets (Wartiovaara et al, 1998). Although
megakaryocytes in the bone marrow produce VEGF (Möhle et al,
1997), the presence of VEGF mRNA and VEGF protein has been
demonstrated to be up-regulated in several tumour types (Brekken
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et al, 1998). Therefore, an important source of circulating VEGF
in cancer patients is presumably the tumour tissue. The hypothesis
is that fast-growing tumours, besides producing angiogenic factors
such as VEGF, also release thrombopoietic cytokines. An increase
in the number of circulating platelets could then, by the uptake of
free VEGF, focus the effect of this angiogenic factor to sites where
coagulation takes place, e.g. a wound or a tumour.
Both thrombopoietin (Kaushansky, 1995) and interleukin-6 (IL-
6) (Ishibashi et al, 1989) potently stimulate platelet production.
Recombinant human thrombopoietin and IL-6 proteins have been
used in clinical trials in cancer patients (Weber et al, 1993;
Vadhan-Raj et al, 1997). Transient stimulations of tumour growth
have been observed during IL-6 treatment, which disappeared
immediately upon cessation of IL-6 treatment (Ravoet et al, 1994).
IL-6 is produced in malignant tumours and in inflammatory tissues
(Rak et al, 1996). IL-6 is up-regulated by hypoxia (Yan et al,
1995), like VEGF and other angiogenic factors. IL-6 expression
is elevated in healing wounds (Mateo et al, 1994). Response
elements for IL-6 signalling are present upstream to the transcrip-
tion initiation site of VEGF (Cohen et al, 1996). Thrombocytosis
is a clinical sign of malignant mesothelioma progression and has
been associated with high levels of circulating IL-6 (Nakano et al,
1998). In inflammatory bowel disease, independent studies have
shown that exacerbation of disease coincided with high serum
levels of angiogenic factors (Bousvaros et al, 1997), with high
serum levels of IL-6 (Bross et al, 1996) and with high platelet
numbers (Lake et al, 1978).
Given these arguments, we compared the serum VEGF, bFGF
and IL-6 concentrations with the platelet numbers in 80 samples
from 50 patients with various types of metastatic cancer. To esti-
mate the biological meaning of serum angiogenic factor levels we
also assessed whether high serum VEGF and bFGF concentrations
concurred with a mitogenic effect on human endothelial cells in
vitro.
PATIENTS AND METHODS
Patients
Of advanced cancer patients, 10 ml of venous blood were drawn
into a serum separator tube (type vacutainer code 607213, Becton-
Dickinson) and immediately centrifuged at 3000 r.p.m for 10 min.
Thereafter the serum was separated and aliquoted in 1.0-ml frac-
tions and stored at –80°C. Eighty samples were randomly selected
from this serum collection, related to 50 patients. Twenty-six
patients had a metastatic breast adenocarcinoma, seven a
metastatic renal carcinoma, six a metastatic ovarian adenocarci-
noma, five a metastatic colorectal adenocarcinoma, two a high-
grade lymphoma, one a high-grade testis tumour, one a metastatic
small-cell lung tumour, one a malignant fibrous histiocytoma and
one had a metastatic carcinoid tumour.
Methods
Serum levels of bFGF and VEGF were determined using two
enzyme-linked immunosorbent assay (ELISA) kits of R&D
Systems (Minneapolis, MN, USA; Quantikine High Sensitivity
human FGF basic and Quantikine human VEGF). Within-assay
reproducibility has been tested before (Dirix et al, 1997). Due to
exhaustion of the serum aliquots, bFGF could not be measured in
four patients.
Serum levels of Il-6 were determined with an ELISA kit of R&D
Systems (Quantikine human IL-6). The assay employs a quantita-
tive sandwich enzyme immunoassay technique combining a bound
monoclonal antibody specific for IL-6 with an unbound enzyme-
linked polyclonal antibody specific for IL-6. Within-assay repro-
ducibility was evaluated on duplicates. When 40 serum samples
from apparently healthy individuals were evaluated by R&D
Systems, 83% had an IL-6 content of less than 3.13 pg ml–1 or the
detection limit. Comparably, IL-6 was undetectable, or was at the
limit of detection of the assay, i.e. 4 pg ml–1, in the serum of normal
subjects in the study of Nakano et al (1998). Thrombocytosis was
defined as a platelet number above 400 ´ 109 1–1. In four patients,
platelet counts were not performed on a sample taken at the time of
serum sampling and were therefore not used.
Endothelial cell proliferation assay
Human umbilical vein endothelial cells (HUVEC) were isolated
according to Jaffe et al (1973) and seeded onto gelatin-coated
plastic. They were maintained in M199 medium supplemented
Table 1 Correlation coefficient r and P-value of the correlation analysis of
the different sets of variables
VEGF IL-6 Platelet n
r/Pr /Pr /P
bFGF 0.06/0.6 0.03/0.8 0.12/0.3
VEGF – 0.55/<10–4 0.61/<10–4
IL-6 – – 0.36/10–3
Platelet n = platelet number. Significant correlations are printed in bold.
Table 2 The comparison of bFGF, VEGF and IL-6 serum levels in patients without thrombocytosis versus patients with thrombocytosis
and according to the median platelet number (platelet n)
Platelet n bFGF (pg ml–1) VEGF (pg ml–1) IL-6 (pg ml–1)
(109 l–1)
≤ 400 (n = 62) 5.43 ± 6.68 (2.52) 351 ± 297 (233) 8.67 ± 22.35 (1.50)
> 400 (n = 14) 9.02 ± 9.19 (6.72) 822 ± 464 (739) 28.54 ± 47.51 (8.72)
P-value 0.10 < 10–4 0.03
≤ median (n = 40) 5.81 ± 7.12 (2.98) 254 ± 186 (191) 5.78 ± 7.13 (1.50)
> median (n = 36) 6.46 ± 7.57 (4.06) 642 ± 431 (562) 19.60 ± 40.96 (3.96)
P-value 0.83 < 10–4 0.08
Mean concentrations ± standard deviation (median) are given. Mann–Whitney U-test.894 R Salgado et al
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with 20% fetal calf serum (FCS), ECGS 0.01 mg ml–1 (Sigma),
heparin 1 U ml–1 and antibiotics. First to second passage cells were
used. All cultures were maintained in a humidified 5% carbon
dioxide incubator at 37°C. Subcultures were obtained by enzyme
treatment (0.05% trypsin, 0.2% EDTA).
For the proliferation assay, 20 000 cells were put into one well
(24-well plate) and allowed to adhere and proliferate for 24 h. The
medium was then changed. In the control wells the standard
medium was put with 20% FCS. In the other wells, the FCS was
replaced by patient serum (20%). After 24 h the endothelial cells
were harvested and the viable cells were selected by trypan blue
dye exclusion and counted in a haematocytometer. All experi-
ments were performed in triplicate. The results were expressed as
the ratio of the number of HUVEC in the wells with the patient
serum versus the number of HUVEC in control wells (percentage).
Twenty serum samples of cancer patients and five samples of
healthy volunteers were randomly taken from the serum collection
of our laboratory. Serum bFGF and VEGF were determined as
described before.
Statistical analysis
Statistical analysis was performed with the Statview 4.51 software
application (Abacus Concepts) on an Apple Macintosh personal
computer. The relation between continuous variables was analysed
by a correlation analysis. Comparisons of continuous variables in
different subgroups were performed by Mann–Whitney U-test and
Kruskal–Wallis test. The differences in fractions of patients/samples
were analysed by a c2 test. A P-value < 0.05 was considered to be
significant.
RESULTS
Forty-two (53%) serum samples from 35 (70%) patients had a
measurable IL-6 content, which was higher than the detection limit
of 3.12 pg ml–1. The mean coefficient of variation of the duplicate
analysis of these samples was 5.7% (n = 42; range 0.53–29.50).
When IL-6 was not detectable in a serum sample, the value of
1.5 pg ml–1 was entered for further analysis, i.e. approximately
50% of the detection limit.
Mean bFGF level was 5.96 pg ml–1 (standard deviation (s.d.)
7.20; median 3.07; range 0.11–33.0; n = 76). Mean VEGF level
was 453 pg ml–1 (s.d. 381; median 314; range 40–2000; n = 80).
Mean IL-6 level was 13.74 pg ml–1 (s.d. 30.42; median 3.42; range
1.50–170.40; n = 80). Mean platelet number was 307 109 l–1 (s.d.
115; median 276; range 132–655; n = 76). Fourteen of 76 (18%)
samples from 13 of 46 (28%) patients showed thrombocytosis.
Results of the correlation analysis of the different sets of vari-
ables are given in Table 1. The strongest correlations were present
between serum VEGF and platelet number (n = 76; r = 0.61;
P < 0.0001) (Figure 1) and between serum VEGF and IL-6 (n = 80;
r = 0.55; P < 0.0001). A correlation was also found between
platelet number and serum IL-6 levels (n = 76; r = 0.36;
P < 0.0011). There was no correlation between bFGF and any of
the other variables.
The comparison of bFGF, VEGF and IL-6 serum levels in
patients without thrombocytosis (n = 33) versus patients with
thrombocytosis (n = 13) is given in Table 2. Median VEGF serum
levels were 3.2 times higher in the latter group (P < 0.0001).
Median IL-6 serum levels were 5.8 times higher when thrombo-
cytosis was present (P = 0.03). The difference of mean bFGF
serum levels was not significant. Comparable results were
obtained when median platelet number, i.e. 276 109 l–1, was taken
as the cut-off value (Table 2).
When the samples were categorized according to the median
serum VEGF level, i.e. 314 pg ml–1, according to the median
platelet number, and according to the detection limit for serum
IL-6, the following distributions of samples were found. Of 40
samples with low serum VEGF, 30 also had a low platelet number.
Of the 36 samples with high serum VEGF, 26 also had a high
platelet number (n = 76; c2 value = 16.95; P < 0.0001). Of the 40
samples with low serum VEGF, 30 also had undetectable low
levels of IL-6. Of the 40 samples with high serum VEGF, 33 had
serum IL-6 levels above the detection limit (n = 80; c2 value =
26.60; P < 0.0001). Of the 40 samples with a low platelet number,
23 also had undetectable low levels of IL-6. Of the 36 samples
with a high platelet number, 23 also had serum IL-6 levels above
the detection limit (n = 76; c2 value = 3.48; P = 0.0622).
Platelet number and IL-6 serum levels co-determined VEGF
serum levels but not bFGF serum levels (Table 3). Serum VEGF
levels were higher (mean serum VEGF of 785 pg ml–1) when both
platelet number and IL-6 serum levels were high, i.e. above the
median value and above the detection limit, respectively, than
when only platelet number or only IL-6 was high (mean serum
VEGF of 384 pg ml–1) (P < 0.0001). When serum bFGF was
analysed in this way, no differences were observed (Table 3).
Table 3 The comparison of bFGF and VEGF serum levels according to
platelet number (platelet n) and IL-6 serum levels
bFGF (pg ml–1) VEGF (pg ml–1)
Platelet n low 5.31 ± 7.70 (1.39) 161 ± 81 (180)
and IL-6 low (n = 23)
Platelet n high 5.73 ± 5.67 (4.54) 384 ± 263 (304)
or IL-6 high (n = 30)
Platelet n high 7.38 ± 8.70 (3.09) 785 ± 423 (760)
and IL-6 high (n = 23)
P-value 0.52 < 10–4
For platelet number the cut-off value was the median. For IL-6 the cut-off
value was the detection limit. Mean concentrations ± standard deviation
(median) are given. Kruskal–Wallis test.
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Figure 1 Correlation between platelet number and serum VEGF
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If, as suggested by Banks et al (1998) the platelets are the major
source of VEGF in the serum, the theoretical VEGF load of
platelets can be calculated by the ratio of VEGF serum concentra-
tion and the platelet number. A mean VEGF load of 1.37 pg VEGF
10–6 platelets was found (s.d. 0.39; range 0.16–3.64; median, 1.16;
n = 76). A significant correlation was found between VEGF load
and serum IL-6 concentration (r = 0.4; P = 0.0003) (Figure 2).
When only samples with a platelet number lower than the median
of 276 109 l–1 were analysed, this correlation became stronger
(r = 0.67; P < 0.0001). The respective coefficient r for the samples
with a high platelet number was 0.39 (P = 0.0171).
When patient sera with a bFGF and a VEGF content higher than
the cut-off values we have previously used, i.e. 7.5 pg ml–1 and
500 pg ml–1 respectively (Dirix et al, 1996; Dirix et al, 1997), were
tested, in most cases (five of eight samples) the HUVEC number
after 24 h was higher than when the sera of apparently healthy
volunteers were used. The opposite was found when patient sera
with low bFGF and/or low VEGF content were assayed: only one
sample out of 12 resulted in a high HUVEC number in the prolif-
eration assay (P = 0.018). The mean proliferation assay result for
the healthy persons was 152%, and was 170% for the patient sera
with elevated bFGF and elevated VEGF as compared to 128% for
the patient sera with low serum bFGF and/or low serum VEGF
content (P = 0.0037) (Table 4).
DISCUSSION
This study supports the role of platelets in the storage of circu-
lating VEGF, as suggested by Verheul et al (1997), Banks et al
(1998) and Wartiovaara et al (1998). A strong correlation was
found between platelet count and serum VEGF concentration in a
cohort of patients with different types of advanced cancer. The
cytokine IL-6 correlated with the total amount of VEGF in the
serum and also with the calculated VEGF content of the platelets,
indicating a more complex indirect angiogenic action of IL-6 than
just the thrombopoietic effect.
As the generation of tumour stroma is remarkably similar to the
healing of wounds (Dvorak, 1986), platelet activation, coagulation
of extravasated plasma fibrinogen and fibrinolysis are important
endpoints of tumour–host cell interactions in growing tumours.
Evidence for platelet activation in cancer patients is based on the
assessment of circulating levels of b-thromboglobulin, a platelet
a-granule component. Levels of b-thromboglobulin were signifi-
cantly elevated, e.g. in prostatic cancer (Yazaki et al, 1987), in
breast cancer (Ferriere et al, 1985) and in small-cell lung cancer
(Milroy et al, 1988), compared with those of healthy individuals.
VEGF appears to be released by activated platelets together with
b-thromboglobulin, suggesting that VEGF is located in the a-
granules of platelets (Möhle et al, 1997; Wartiovaara et al, 1998).
Clotting of platelet-rich plasma (PRP) prepared from the blood of
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Figure 2 Theoretical VEGF content of platelets versus IL-6 serum levels for samples with a platelet number lower than the median (A; n = 40) and for samples
with a platelet number higher than the median (B; n = 36). Respective r and P-values are: 0.67/<10–4 and 0.39/0.017
Table 4 HUVEC proliferation expressed as the ratio of the number of
HUVEC in the wells with the patient serum versus the number of HUVEC in
the control wells with fetal calf serum
HUVEC proliferation bFGF (pg ml–1) VEGF (pg ml–1)
(% of control)
bFGF high and VEGF high (n = 8)
228 10.30 763
200 17.00 813
184 17.00 1490
160 17.00 796
160 32.70 670
152 11.60 767
152 7.51 957
126 11.80 632
(170 ± 32; 160)a
bFGF low and/or VEGF low (n = 12)
155 0.49 206
150 17.00 389
137 0.51 105
136 0.55 185
135 0.49 109
134 1.85 172
134 0.87 226
129 1.01 1130
126 0.31 115
113 4.39 1650
97 33.00 244
97 1.30 1160
(128 ± 18; 134)a
The mean proliferation assay result for healthy persons (n= 5) was 152%
(s.d. 31). Results printed in bold are above this mean value. aBetween
brackets, the mean ± s.d.; median values for HUVEC proliferation (%) are
given. Mann–Whitney UP -value: 0.0037.896 R Salgado et al
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eight healthy individuals with thrombin resulted in higher VEGF
levels than when platelet-free plasma was used (Banks et al, 1998).
The VEGF levels obtained after the clotting of the PRP correlated
with the respective serum VEGF levels. The theoretical VEGF
load of platelets, i.e. the VEGF concentration found after activa-
tion of the platelets calculated in terms of the number of platelets
present, was highly comparable in PRP and serum. These observa-
tions support the hypothesis that platelets are an important source
of circulating VEGF. In 27 patients with advanced breast cancer
undergoing chemotherapy, a correlation (r = 0.8; P < 0.01)
between serum VEGF levels and platelet counts was reported by
Verheul et al (1997). In the group of eight healthy individuals
(Banks et al, 1998), serum VEGF just failed to achieve a signifi-
cant correlation with platelet number (r = 0.62; P = 0.1). In our
population of 50 patients, corresponding to 80 blood samples, with
various types of advanced cancer, a highly significant correlation
between platelet number and serum VEGF concentration was
found (r = 0.61; P < 10–4). These results are in accordance with the
reduced survival rates of cancer patients with preoperative
thrombocytosis, e.g. in lung cancer (Møller Pedersen et al, 1996).
We have indeed shown that high serum VEGF, and thus high
platelet number, indicates fast growth kinetics in several tumour
types (Dirix et al, 1996; Dirix et al, 1997). It is conceivable that
platelets provide a means to concentrate the effect of secreted
growth factors, e.g. VEGF, onto sites of perturbed integrity of the
vascular wall, as present during wound healing and tumour
growth. This scavenger function of platelets also conforms to the
lack of apparent angiogenesis observed outside of the tumour in
patients with high amounts of circulating VEGF protein. Although
clear evidence for the endocytic uptake of VEGF by platelets is
absent, the incorporation of other circulating proteins into platelet
granules and into megakaryocytes has been extensively studied
(Handagama et al, 1987; Harrison et al, 1989).
Since plasma VEGF levels are very low (Banks et al, 1998), and
probably as a consequence of inefficient inhibition of platelet activa-
tion during sample handling, platelets can be regarded as the trans-
porters of the active and stable fraction of circulating VEGF. The in
vitro HUVEC proliferation assay results indeed suggest that the
concentration of VEGF measured in the serum reflects the biological
activity of VEGF. Given the considerable variability of the theoret-
ical VEGF load of platelets (range: 0.16–3.64 pg VEGF 10–6
platelets), serum VEGF does not seem to be a simple reflection of the
number of circulating platelets. As a practical conclusion, we there-
fore suggest using serum VEGF and not plasma VEGF as suggested
by Banks et al (1998), as a measure of circulating VEGF. Since other
circulating blood cells may also contain VEGF, measuring VEGF in
whole blood might even reflect the active VEGF concentration more
accurately (P Salven, personal communication).
We measured the serum IL-6 levels in the cohort of 50 patients
with advanced cancer, (1) because IL-6 serum levels correlate with
platelet number (Nakano et al, 1998) and intravenous administration
of recombinant human IL-6 results in elevation of the platelet
number (Clarke et al, 1996); (2) because IL-6 production is
increased in tumour tissue (Rak et al, 1994; Degeorges et al, 1996)
and during wound healing (Mateo et al, 1994); and (3) because tran-
sient tumour-stimulating effects have been observed during IL-6
treatment of cancer patients (Ravoet et al, 1994) and high IL-6 levels
are associated with adverse prognosis in several tumour types and
benign angiogenic diseases (Blay et al, 1992; Bross et al, 1996).
Serum levels of IL-6 correlate with platelet number and with
serum VEGF concentration, but not with serum bFGF concentration.
This result can be explained by the thrombopoietic action of IL-6 and
the storage of VEGF within platelets. The calculated VEGF content
of the platelets is larger when serum IL-6 levels are higher. This result
implies an additional effect of IL-6 on VEGF production. Transient
expression of IL-6 mRNA was shown in endothelial cells during the
physiologic angiogenic processes associated with the development of
ovarian follicles and with the embryonic implantation in the maternal
decidua (Motro et al, 1990). Treatment of various cell lines, e.g.
derived from an epidermoid human carcinoma and a glioma cell line,
with IL-6 resulted in the induction of VEGF mRNA (Cohen et al,
1996). The effect of IL-6 on VEGF expression is mediated by
specific DNA motifs located on the putative promotor region of
VEGF as well as by specific elements in the 5¢-untranslated region.
Hypoxia has been shown to induce IL-6 mRNA and IL-6 protein in
cultured human endothelial cells (Yan et al, 1995). IL-6 can thus be
regarded as an indirect angiogenic factor produced by stromal cells
and by tumour cells.
Although in benign prostate hyperplasia (Degeorges et al, 1996)
and in early-stage radial melanoma growth phase (Rak et al, 1994),
stroma-derived IL-6 might function as a growth inhibitor of
tumour cells, at least in more advanced cancer, IL-6 might stimu-
late tumour growth by increasing the amount of active VEGF,
stored in the platelets. The stimulation of platelet production by
tumour-derived IL-6 favours the endocrine effect of angiogenic
factors and facilitates the development of secondary tumours in
distant tissues, exemplifying the parasitic nature of cancer.
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